HER-2/EGFR antagonists (SUGEN/Baxter Oncology)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameHER-2/EGFR antagonists (SUGEN/Baxter Oncology)
Drug Alias NameEGF receptor tyrosine kinase inhibitors (SUGEN)HER-2 antagonists (SUGEN/ASTA Medica)EGFR antagonists (SUGEN/Baxter Oncology)Pan-HERSU-11464 +[6] 
ClassificationSmall molecules
Mechanisms of ActionAnticancer protein kinase inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonistsEpidermal growth factor receptor erbB1 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsPsoriasisProstatic NeoplasmsLung Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSugen Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSugen LlcAsta Medica AgBaxter Oncology Gmbh
Active IndicationsN/A
Inactive IndicationsPsoriasisProstatic NeoplasmsLung Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A